Gaurav Shah
CIK: 0001725922
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ROCKET PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (17 total)
- Aug 18, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct2.3K shares at avg. $3.38$8K - Aug 13, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct2.8K shares at avg. $3.38$10K - May 21, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct55.7K shares at avg. $3.09$172K - May 21, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Exercise(M)Direct76.5K shares at avg. $1.69$129K - May 19, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct2.4K shares at avg. $3.01$7K - May 13, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct2.7K shares at avg. $3.61$10K - Feb 18, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct6K shares at avg. $3.34$20K - Feb 13, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct12.3K shares at avg. $3.31$41K - Feb 11, 2026RCKT
ROCKET PHARMACEUTICALS, INC.
Award(A)Direct286K shares- - Nov 18, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct6.3K shares at avg. $2.98$19K - Aug 18, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Tax Payment(F)Direct2.2K shares at avg. $3.05$7K - May 20, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct2.3K shares at avg. $6.45$15K - May 16, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct3.6K shares at avg. $6.53$24K - Apr 10, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Purchase(P)Direct20K shares at avg. $5.08$102K - Feb 21, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct16.3K shares at avg. $10.58$172K - Feb 11, 2025RCKT
ROCKET PHARMACEUTICALS, INC.
Award(A)Direct81.7K shares- - Nov 21, 2024RCKT
ROCKET PHARMACEUTICALS, INC.
Sale(S)Direct11.1K shares at avg. $13.05$145K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 18, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 2,293 | $3.38 | $7,753 | Direct |
| Aug 13, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 2,837 | $3.38 | $9,592 | Direct |
| May 21, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 55,684 | $3.09 | $171,841 | Direct |
| May 21, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Exercise(M) | 76,490 | $1.69 | $129,345 | Direct |
| May 19, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 2,409 | $3.01 | $7,261 | Direct |
| May 13, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 2,728 | $3.61 | $9,837 | Direct |
| Feb 18, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 5,990 | $3.34 | $19,995 | Direct |
| Feb 13, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 12,279 | $3.31 | $40,668 | Direct |
| Feb 11, 2026 | RCKT ROCKET PHARMACEUTICALS, INC. | Award(A) | 286,028 | - | $0 | Direct |
| Nov 18, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 6,276 | $2.98 | $18,721 | Direct |
| Aug 18, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Tax Payment(F) | 2,234 | $3.05 | $6,814 | Direct |
| May 20, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 2,253 | $6.45 | $14,523 | Direct |
| May 16, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 3,621 | $6.53 | $23,638 | Direct |
| Apr 10, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Purchase(P) | 20,000 | $5.08 | $101,600 | Direct |
| Feb 21, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 16,303 | $10.58 | $172,486 | Direct |
| Feb 11, 2025 | RCKT ROCKET PHARMACEUTICALS, INC. | Award(A) | 81,655 | - | - | Direct |
| Nov 21, 2024 | RCKT ROCKET PHARMACEUTICALS, INC. | Sale(S) | 11,091 | $13.05 | $144,782 | Direct |
1-17 of 17 transactions
About Shah Gaurav
Shah Gaurav (SEC CIK 0001725922) files insider reports with the SEC as CEO of ROCKET PHARMACEUTICALS, INC. (RCKT).
Signal8 holds 16 ownership filings by Shah Gaurav, all Form 4s, filed between Nov 25, 2024 and Aug 20, 2026. Those filings report 17 transactions, from Nov 21, 2024 to Aug 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Shah Gaurav's filings is in CRANBURY, NJ.
Recent filings by Shah Gaurav
- Aug 18, 2026: Open-market sale of RCKT shares (Form 4, code S).
- Aug 13, 2026: Open-market sale of RCKT shares (Form 4, code S).
- May 21, 2026: Open-market sale of RCKT shares (Form 4, code S).
- May 21, 2026: Option exercise of RCKT shares (Form 4, code M).
- May 19, 2026: Open-market sale of RCKT shares (Form 4, code S).
Other insiders filing for ROCKET PHARMACEUTICALS, INC. (RCKT)
- Wilson Martin, General Counsel
- Stevens Christopher James, Chief Operating Officer
- Chaudhuri Sarbani
- SOUTHWELL DAVID P, Director
- Manhede Joseph, Principal Accounting Officer
- WONG RODERICK, Director